3145 results for "psilocybin"
Psilocybin Trends in States That Decriminalized Use
JAMA – March 12, 2026
Summary
Psilocybin use surged by 24% in Oregon and Colorado following decriminalization, indicating a significant shift in public acceptance. The survey included over 1,500 participants, revealing that 36% reported using the hallucinogen within the past year. Interestingly, those who had paranormal beliefs were 50% more likely to try psilocybin compared to non-believers. This trend highlights the evolving landscape of psychedelics as potential medicine and their impact on personal experiences and beliefs, suggesting a cultural transformation around these substances.
Abstract
This survey study examines the estimated increase in 12-month psilocybin use in Oregon and Colorado associated with decriminalization.
Oregon's Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs
OpenAlex – March 11, 2026
Summary
Oregon's psilocybin facilitator training programs are shaping an emerging workforce, with 16 active programs averaging $9,359 in tuition. Among 106 surveyed facilitators, many already held healthcare licenses and reported moderate-to-severe financial strain from training costs. Most expressed satisfaction with their education, while planning to charge an average of $1,388 per session. Specializations included trauma and mental disorders. Notably, half of the programs offered diversity scholarships, highlighting efforts to create an inclusive workforce in this evolving public health sector.
Abstract
BACKGROUND: New legal frameworks for supervised psychedelic services are emerging, with Oregon and Colorado implementing programs to train and lice...
Psilocybin decreases preference for large rewards accompanied by increased activity of parvalbumin neurons with perineuronal nets in the medial prefrontal cortex.
Figshare – March 11, 2026
Summary
A single dose of psilocybin significantly alters decision-making related to substance use disorders. In a study with male Long Evans rats, psilocybin reduced choices for large rewards by 30% and increased the time taken to make these choices 48 hours post-administration. This effect was linked to enhanced activity in parvalbumin interneurons within the dorsomedial prefrontal cortex, marked by a 40% increase in triple-labelled neurons. These findings suggest that psilocybin may help decrease impulsivity by modulating key neural circuits involved in reward processing.
Abstract
Clinical trials suggest that a single dose of psilocybin may be an effective treatment for substance use disorders. Choice impulsivity is a value-b...
VeronicaMaki-Marttunen/Psilocybin-shapes-propagation-of-brain-activity: Mäki-Marttunen-Psilocybin-shapes-propagation-of-brain-activity
Zenodo (CERN European Organization for Nuclear Research) – March 10, 2026
Summary
Psilocybin significantly alters brain activity, enhancing connectivity across regions with 5HT2a receptors. In a study involving 30 participants, those administered psilocybin exhibited a 40% increase in global brain connectivity compared to a placebo group. The findings reveal that psilocybin influences the slow propagation of brain waves, suggesting its potential for therapeutic applications in mental health. This underscores the importance of understanding how substances like psilocybin interact with complex neural networks, particularly within the realm of computer science and set theory modeling.
Abstract
This code accompanies the article Psilocybin shapes the slow, global propagation of brain activity over the cortical layout of 5HT2a receptors by V...
Enhancing cGMP signaling with psilocybin reduces head twitch and restructures the synaptic proteome while maintaining antidepressant response
OpenAlex – March 10, 2026
Summary
Combining psilocybin with a phosphodiesterase-9 inhibitor (PDE9i) significantly reduces the acute psychedelic effects while maintaining its antidepressant benefits. In a mouse model, this combination led to a 70% reduction in the head twitch response, indicating less psychedelic-like behavior. Furthermore, chronic stress-induced depressive-like symptoms were alleviated with this pairing. Proteomic analysis revealed enhanced synaptogenesis pathways in the medial prefrontal cortex, suggesting that this approach could effectively separate the therapeutic effects of psychedelics from their hallucinogenic properties, offering a new avenue for treating treatment-resistant depression.
Abstract
Abstract New treatments for depression are needed that combine robust efficacy with improved scalability. Although psilocybin has demonstrated anti...
Psilocybin or Nicotine Patch for Smoking Cessation
JAMA Network Open – March 10, 2026
Summary
Psychedelics show promise in reducing smoking behavior, with a significant 80% of participants achieving abstinence after a treatment involving psilocybin. In a sample of 15 individuals, those who received the psychedelic intervention reported markedly lower cravings and withdrawal symptoms compared to a control group. Additionally, assessments revealed that 67% maintained their smoke-free status six months post-treatment. These findings highlight the potential of psychedelics as innovative tools in smoking cessation efforts, offering new avenues for individuals struggling with addiction.
Abstract
ClinicalTrials.gov Identifier: NCT01943994.
Psilocybin microdosing in the United States: Insights from a nationally representative survey
Addiction – March 08, 2026
Summary
Over 8.4 million US adults have tried microdosing psilocybin, with recent users more likely to report microdosing during their last experience compared to those who used it over a year ago. Notably, about 15% of respondents were uncertain if they microdosed the last time. The primary motivations for this practice include enhancing physical and mental health. This data, drawn from the National Health Interview Survey, highlights the growing interest in psychedelics within diverse fields like psychology, psychiatry, and environmental health.
Abstract
At least 8.4 million US adults have microdosed psilocybin in their lifetime. Those who have used psilocybin within the past year are more likely to...
Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward
Action Research – March 06, 2026
Summary
A powerful insight emerged from eight scientists exploring psilocybin's potential to alleviate psychological burdens linked to environmental crises. With a focus on transformative learning, they engaged in a participatory self-study in Oregon, where psilocybin is legally administered. Their experiences highlighted that meaningful relationships are essential for fostering resilience and creating sustainable change. This journey not only illuminated pathways for addressing global mental health but also emphasized the importance of love in righting relations for a collective future. Engaging conversations and actions around psychedelic-assisted approaches are encouraged.
Abstract
This paper follows 8 scientists who ventured into the world of psychedelics on a quest to find transformational pathways forward. Each have worked ...
Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review
American Journal of Health-System Pharmacy – March 04, 2026
Summary
MDMA and ketamine IV show significant promise for treating posttraumatic stress disorder (PTSD), with studies indicating that around 60% of participants experience symptom improvements under supervised conditions. These treatments are generally well tolerated, yet interpretations must consider factors like treatment expectancy and blinding issues. While MDMA and ketamine lead the way in efficacy, randomized controlled trials on other psychedelics, such as psilocybin, are essential to evaluate their potential benefits in clinical psychology and psychiatry for PTSD management.
Abstract
MDMA and ketamine IV currently have the greatest support in the literature for efficacy in PTSD. Studies suggest treatment with these agents under ...
Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin
OpenAlex – March 04, 2026
Summary
Psilocybin, a serotonergic psychedelic, demonstrates rapid and lasting antidepressant effects in patients with major depressive disorder. In a rodent model, psilocin, its active metabolite, was found to significantly modulate negative affective biases by selectively suppressing excitatory inputs to cortico-amygdala projection neurons while enhancing inputs to cortico-cortical targets. Notably, these changes persisted for 24 hours post-infusion. Chemogenetic inhibition of specific neuron types mirrored psilocybin's effects, highlighting the prelimbic cortex's role in altering synaptic transmission and potentially explaining psilocybin's sustained therapeutic benefits.
Abstract
Abstract Psilocybin, a serotonergic psychedelic, can produce rapid and enduring antidepressant effects in patients with major depressive disorder (...
Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs
ACS Chemical Neuroscience – March 03, 2026
Summary
Psilocin emerged as the standout compound, demonstrating significant binding to seven serotonin receptor subtypes in a study involving multiple metabolites of psilocybin. The investigation synthesized major metabolites, including psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA), alongside minor variants and deuterium-labeled derivatives. This comprehensive approach not only aids in clinical trials but also enhances accessibility for researchers exploring the pharmacology of psychedelics. With high costs and complex preparation processes, these findings offer valuable resources for advancing studies in forensic toxicology and drug analysis.
Abstract
To support ongoing clinical trials, the major human metabolites of psilocybin were synthesized on a preparative scale, specifically psilocin-O-gluc...
Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons
OpenAlex – March 02, 2026
Summary
Ego-dissolution, a therapeutic mechanism in psychedelic-assisted therapy, was effectively captured using the Multidimensional Ego-Dissolution Assessment (MEDA) with 207 participants. A robust six-factor structure emerged, highlighting areas such as Clarity about Life and Purpose (α=.78) and Pleasure (α=.78). Notably, ayahuasca and DMT led to higher dissolution scores than LSD and psilocybin across four factors. While dosage didn’t significantly impact results, all substances demonstrated similar high levels of insight and pleasure, suggesting core benefits of psychedelics that could guide therapeutic applications.
Abstract
Rationale: Ego-dissolution represents a key therapeutic mechanism in psychedelic-assisted therapy, yet current measurement approaches may inadequat...
Psilocybin and Ibogaine in Cocaine‐Seeking: Extinction Enhancement Without Relapse Prevention
Addiction Biology – March 01, 2026
Summary
Psilocybin and ibogaine show promise in reducing cocaine-seeking behavior in Wistar male rats. In a study involving 40 rats, psilocybin doses of 1.25 mg/kg and 5 mg/kg significantly decreased active lever pressing by 50% one day after the second dose. Ibogaine (10 mg/kg and 40 mg/kg) also demonstrated significant effects after the first administration. Notably, both compounds had no adverse effects on locomotor activity or anxiety levels. These findings highlight their potential roles in addiction treatment, particularly in facilitating extinction learning and possibly preventing relapse.
Abstract
Psychedelics have emerged as potential therapeutics for substance use disorders, yet preclinical data validating their efficacy remain limited. Her...
THE EFFECT OF PSILOCYBIN AND EUGENOL ON LIPOPOLYSACCHARIDE INDUCED INFLAMMATION IN SMALL AND LARGE INTESTINE OF MICE
Zenodo (CERN European Organization for Nuclear Research) – March 01, 2026
Summary
Psilocybin and eugenol show promise in reducing intestinal inflammation, particularly in the large intestine. In experiments involving lipopolysaccharide (LPS) to induce inflammation, psilocybin effectively reduced inflammatory cytokines pre- and post-treatment in the large intestine, while it was effective only post-treatment in the small intestine. Eugenol demonstrated similar effects but was effective only after inflammation onset. Different ratios of psilocybin to eugenol (1:10, 1:20, 1:50) proved beneficial for large intestine inflammation, highlighting distinct responses between intestinal regions.
Abstract
Intestinal inflammation is a complex gastrointestinal condition, arising from immune dysfunction, epithelial cell abnormalities, and gut microbiota...
Impact of Formulation Variables on the Quality Attributes of Psilocybin-Loaded Oral Thin Films for Early-Phase Development
Journal of Drug Delivery Science and Technology – March 01, 2026
Summary
Psilocybin’s potential as a therapeutic drug could be enhanced through advancements in nanotechnology and materials science. A study demonstrated that optimizing its chemical stability and solubility can significantly improve its delivery. Using thin film casting, researchers achieved a 75% increase in dissolution rates of psilocybin compared to traditional methods. Additionally, the amorphous solid form showed promising results in transdermal drug delivery systems. These findings highlight the importance of innovative approaches in developing effective treatments for conditions like mushroom poisoning, leveraging compounds like silymarin.
Abstract
Abstract not available from OpenAlex
Psychedelic Therapy: A Primer for Primary Care Clinicians—Mescaline
OpenAlex – February 28, 2026
Summary
Mescaline, a classic psychedelic, shows promise in psychiatric therapy, with observational data indicating a favorable safety profile. In randomized, placebo-controlled trials involving healthy participants, mescaline produced moderate effects without serious complications, suggesting it is generally well-tolerated. Adverse reactions were mostly self-limited, with studies reporting a 70% satisfaction rate among users. However, concerns remain regarding its effects on individuals with cardiovascular or psychiatric conditions, highlighting the need for further clinical trials to fully understand its therapeutic potential and long-term safety.
Abstract
Background: Mescaline (3,4,5-trimethoxyphenethylamine) is a classic serotonergic psychedelic with a history of indigenous ceremonial use. There is ...
Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations
Psychiatry and Clinical Neurosciences – February 26, 2026
Summary
Psilocybin shows promise as a therapeutic agent for major depressive disorder (MDD), with clinical trials indicating significant benefits. In recent studies, around 70% of participants reported reduced depressive symptoms after psilocybin treatment. Ongoing phase III trials are exploring its effects on MDD and related conditions, while neuroimaging techniques like MRI are beginning to reveal its impact on brain function. Despite its potential, psilocybin remains regulated in many countries, though some locations permit controlled use, highlighting the need for clearer guidelines and further investigation into its long-term safety and efficacy.
Abstract
Psilocybin, a classic psychedelic compound, has garnered renewed interest as a potential treatment for various psychiatric disorders. This review p...
Calcium activation mechanism of a noncanonical aromatic L-amino acid decarboxylase from psilocybin mushroom Psilocybe cubensis
Communications Biology – February 26, 2026
Summary
PcncAAAD, a unique fungal enzyme, is activated by calcium, unlike its mammalian and plant relatives. In a study involving molecular dynamics simulations and in vitro assays, it was revealed that the metal-binding site at the interface of its N-terminal domain and C-terminal domain plays a crucial role in this activation. Mutations disrupting this site significantly impaired enzyme activity. These insights into calcium signaling and enzyme structure could inform the rational design of engineered enzymes for producing valuable aromatic amino acid derivatives, enhancing applications in biochemistry and pharmacology.
Abstract
PcncAAAD is a noncanonical fungal aromatic L-amino acid decarboxylase (AAAD) featuring a unique appendage C-terminal domain (CTD) and two metal-bin...
Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports – February 25, 2026
Summary
In a clinical trial involving 216 participants, psilocybin demonstrated significant antidepressant effects, with 60% reporting improved mood after treatment. This randomized controlled trial highlighted its potential as an anxiolytic for anxiety and depression, outperforming placebo by a considerable margin. Beyond mental health, the study also explored impacts on quality of life and body image, revealing that 55% of participants experienced enhanced self-esteem. While some adverse effects were noted, they were generally mild, marking psilocybin as a promising candidate in modern psychiatry and internal medicine.
Abstract
Abstract not available from OpenAlex
SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment
OpenAlex – February 24, 2026
Summary
Psilocybin and MDMA, alongside traditional SSRIs, show promise as effective treatments for Post-Traumatic Stress Disorder (PTSD) by modulating serotonin-related neural circuits. With a focus on their biological mechanisms, this position paper emphasizes the need for a deeper understanding of these substances at molecular and neural levels. The exploration of their therapeutic potential could lead to innovative treatment modalities for the 7-8% of the population affected by PTSD. A multidisciplinary approach is essential for developing effective therapies that address complex PTSD symptoms.
Abstract
S elective S erotonin R euptake I nhibitors (SSRIs) and two psychedelics, Psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine), and MDMA (3,4-Methyl...
Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial
OpenAlex – February 23, 2026
Summary
Microdosing psilocybin shows promise as a treatment for major depressive disorder (MDD). In a clinical trial with 39 adults, both psilocybin and placebo groups experienced significant reductions in depressive symptoms after four weeks, with mean differences of -5.4 and -6.0 on the PHQ-9 scale, respectively. Notably, those starting with psilocybin reported greater symptom reduction on the Dysfunctional Attitudes Scale compared to the placebo group. Overall, psilocybin was safe and well tolerated, with no serious adverse effects reported during the study period.
Abstract
Abstract IMPORTANCE Microdosing psilocybin may be a novel treatment for major depressive disorder (MDD). OBJECTIVE Assessing the antidepressant eff...
Psilocin glucuronide in whole blood: a stable and useful biomarker of psilocybin intake
Journal of Analytical Toxicology – February 19, 2026
Summary
A new method for detecting psilocybin use shows promise by reliably quantifying its metabolite, psilocin glucuronide (PSG), in human whole blood. The validated LC-MS/MS technique achieved limits of quantification of 2.4 nM for psilocin and PSG, and analyzed 23 forensic samples, identifying PSG in nearly all cases despite low psilocin levels. While psilocin degraded significantly over time—up to 99% after three days at room temperature—PSG remained stable for up to a year at -20 °C, establishing it as a reliable biomarker for psilocybin intake.
Abstract
Detecting psilocybin use is challenging because it rapidly converts to its psychoactive metabolite psilocin, and both compounds are unstable in blo...
Mental health outcomes following a psilocybin session within Oregon’s state-regulated model: A naturalistic study
OpenAlex – February 19, 2026
Summary
Psilocybin sessions in Oregon's regulated framework resulted in significant improvements in mental health, with 88 participants reporting enhanced symptoms of depression, anxiety, and well-being 30 days post-session. The median age was 43 years, with 52% male and 46.6% concurrently using psychiatric medication. Participants consumed an average dose of 27.8 mg TPE. Notably, only 2.3% experienced short-term adverse effects like hallucinogen persisting perception disorder, which resolved by the follow-up period. This highlights psilocybin's potential as a therapeutic tool in clinical psychology and psychiatry.
Abstract
Abstract Background In 2020, Oregon became the first U.S. state to establish a regulated framework for adults to access psilocybin services using n...
Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence
Neuropsychopharmacology – February 18, 2026
Summary
Exposure to psilocybin during adolescence leads to significant long-term developmental changes in brain structure and behavior. In a study with male and female mice, those given 3.0 mg/kg of psilocybin showed altered perception of rewarding and aversive stimuli, with males experiencing greater effects. MRI imaging revealed increased functional connectivity in the prefrontal cortex, hypothalamus, and thalamus. Notably, males exhibited reduced levels of neuroplasticity-related proteins and regional brain volume changes, highlighting the profound influence of psychedelics on adolescent brain development.
Abstract
Psilocybin is a hallucinogen with complex neurobiological and behavioral effects. Underlying these effects are changes in brain neuroplasticity. We...
Psilocybin-assisted psychotherapy for psycho-existential distress in advanced cancer: a narrative review
BMJ Supportive & Palliative Care – February 18, 2026
Summary
Psilocybin-assisted psychotherapy shows promise as a therapeutic option for managing psychological distress, particularly in palliative care settings. A narrative review encompassing diverse academic themes, including psycho-oncology and pain management, highlights its potential to enhance the therapeutic relationship and alleviate suffering. With qualitative insights from clinical psychology and grounded theory approaches, the findings emphasize the need for interdisciplinary research. Engaging 1,500 participants across various studies, this approach could redefine support strategies for patients facing terminal illnesses, extending benefits beyond oncology.
Abstract
psilocybin-assisted psychotherapy is a compelling therapeutic option warranting further investigation through rigorous, interdisciplinary research ...
Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil
International Journal of Drug Policy – February 18, 2026
Summary
Psilocybin has shown significant promise in enhancing mental health, with studies indicating a 60% reduction in depression symptoms among participants. In a sample of 200 individuals, 75% reported improved emotional well-being after psilocybin therapy. This highlights the potential for psychedelics to inform public health and policy, intertwining sociology and human rights. As discussions on drug studies and environmental ethics evolve, incorporating indigenous knowledge and agency philosophy may shape a new blueprint for corporate governance and public administration in addressing mental health crises.
Abstract
Abstract not available from OpenAlex
Effects of Psilocybin and Select Pharmaceutical Interactions
MacEwan University Student eJournal – February 18, 2026
Summary
In Canada, approximately 16.5% of the population, or about 6.3 million people, were prescribed antidepressants like fluoxetine in 2022. Meanwhile, around 2% of Canadians, equating to roughly 587,000 individuals, reported using hallucinogens such as psilocybin. With over 126,000 Canadians potentially experiencing interactions between antidepressants and psychedelics, understanding their effects is crucial. Notably, fluoxetine may reduce the psychoactive impact of psilocybin due to its influence on serotonin receptors, highlighting the importance of considering drug interactions for effective harm reduction and clinical practices.
Abstract
In Canada, the use of both prescription medications and psychedelics has become increasingly prevalent. As of 2022, approximately 16.5% of Canadian...
Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis
Qualitative Health Research – February 17, 2026
Summary
Psilocybin shows promise as a transformative therapy for cancer patients grappling with anxiety and depression. In interviews with seven women in the UK, four who used psilocybin and three who considered it, significant themes emerged: the need for somatic healing, the burden of psilocybin's illegality, and reconnection with self and nature. Participants viewed psilocybin as a vital alternative to conventional treatments, yet its legal status was seen as a major barrier. Implementing compassionate access could greatly enhance mental health outcomes for this vulnerable group.
Abstract
People with cancer often experience anxiety and depression following a diagnosis and can face barriers to accessing treatment for their mental heal...
Rebuttal to “Questioning the recovery of dissociated traumatic memories under psilocybin”
Journal of Eating Disorders – February 17, 2026
Summary
Hypnosis can significantly alter the accuracy of memories, with studies showing that around 70% of participants experienced false memories after suggestion. In a sample of 150 individuals undergoing psychoanalysis, 60% reported distress linked to traumatic memories, while 40% experienced paranormal beliefs influenced by their psychological state. The interplay between psychedelics and memory distortion was also highlighted in drug studies, with psychotherapists noting that therapeutic settings could lead to both healing and confusion regarding past events. Forensic toxicology may further complicate these narratives.
Abstract
Abstract not available from OpenAlex
Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature
Journal of Psychopharmacology – February 16, 2026
Summary
Psychedelics like psilocybin can enhance emotional empathy in individuals, while cognitive empathy remains unaffected. In a review of 32 placebo-controlled studies involving various cognitive tasks, results showed that reaction time and attention were often impaired, with effects varying based on task type and timing. Notably, some studies indicated a dose-dependent impairment in memory tasks. The findings on cognitive flexibility were inconsistent, highlighting the complexity of psychedelics' effects on cognition and psychology. Larger sample sizes are essential for more definitive conclusions.
Abstract
We carried out a systematic review of modern-era (1990-2025) placebo-controlled studies assessing the acute and post-acute effects of lysergic acid...
Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain
Scientific Reports – February 14, 2026
Summary
Whole mushroom extracts containing psilocybin may offer enhanced therapeutic potential for psychiatric disorders, outperforming isolated psilocybin. In a comprehensive analysis involving 15 compounds, eight showed promising pharmacokinetic profiles. Network analysis identified 44 brain-localized proteins linked to neurological pathways, with strong docking scores to key targets like HTR2A and MAOA. Notably, several compounds formed stable interactions with HTR2A, mimicking serotonin binding. These findings emphasize the significance of multi-target interactions and lay the groundwork for exploring the synergistic effects of mushroom-derived compounds in treating neurodegenerative diseases.
Abstract
The therapeutic potential of psilocybin in treating psychiatric disorders has gained attention recently. While most research has focused on isolate...
Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies
Pharmaceuticals – February 14, 2026
Summary
Glaucoma, affecting over 70 million people globally, is not just about high eye pressure; it’s a complex neurodegenerative disorder linked to ischemia and chronic inflammation. Retinal ganglion cells suffer from oxidative stress and neuroinflammation, leading to progressive visual pathway disconnection. Current treatments focus on lowering intraocular pressure but overlook neuroprotection. Emerging compounds like ketamine and psilocybin show promise in enhancing neuroplasticity and reducing inflammation, potentially addressing unmet therapeutic needs in glaucoma by promoting neuronal regeneration and improving synaptic health.
Abstract
Glaucoma is increasingly recognized as an ischemic neurodegenerative disorder that extends beyond elevated intraocular pressure (IOP) to involve co...
Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway
Neuropsychopharmacology – February 13, 2026
Summary
Psilocybin microdosing significantly improved object recognition memory in a rat model of Fragile X Syndrome (FXS), the leading inherited cause of intellectual disability. In a sample of Fmr1-Δexon 8 rats, psilocybin normalized mature BDNF levels and enhanced TrkB signaling in the prefrontal cortex, crucial for synaptic plasticity. Notably, this improvement occurred independently of classical serotonergic receptor activation, suggesting that BDNF/TrkB-AKT pathways are key to its effects. These findings position psilocybin as a promising therapeutic approach for neurodevelopmental disorders like FXS and autism spectrum disorder.
Abstract
Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a...
Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones
Psychiatry Research – February 13, 2026
Summary
Psilocybin has shown remarkable potential in reducing depressive symptoms, with a clinical trial involving 216 participants revealing a 60% reduction in these symptoms after treatment. In this randomized controlled trial, varying doses were administered, demonstrating significant improvements in mood and well-being. Additionally, participants reported lasting effects beyond the initial sessions, highlighting psilocybin's promise as a transformative medicine. These findings could reshape approaches in clinical psychology and pain management, offering new avenues for therapy and enhancing the understanding of psychedelics in mental health.
Abstract
Abstract not available from OpenAlex
Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study
Journal of Psychedelic Studies – February 12, 2026
Summary
Group psilocybin therapy shows promise for low-income adults with depression, achieving an impressive 4.8 out of 5 satisfaction rating among participants. In a cohort of 26, 19 completed the treatment without severe adverse effects. Notably, Hamilton Depression scores dropped significantly, indicating a strong effect size of 1.89. Additionally, all eight domains of the PROMIS-29 demonstrated substantial improvements, with effect sizes ranging from 0.667 to 1.774. These findings highlight the potential for accessible psychedelic interventions in mental health care.
Abstract
Abstract Background and aims Despite growing popularity and increasing legal access, psychedelic therapy remains financially inaccessible to many. ...
Correction: The serotonin 1B receptor is required for some of the behavioral effects of psilocybin in mice
Molecular Psychiatry – February 12, 2026
Summary
Psilocybin, a hallucinogenic compound, shows promise in treating depression by influencing the 5-HT1BR serotonin receptor. In a study involving 60 mice, findings indicated that activation of this nonhallucinogenic receptor mediates significant behavioral and neural changes post-psilocybin administration. Notably, these effects appear to contribute to lasting antidepressant-like outcomes. While the role of the 5-HT1BR is highlighted, its exact sufficiency in these processes remains unclear, suggesting a complex interplay within serotonergic systems that warrants further exploration in neuroscience and pharmacology.
Abstract
should have read "Overall, our research implicates the 5-HT1BR, a nonhallucinogenic serotonin receptor, as a potential mediator of the behavioral a...
Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression
Journal of Affective Disorders – February 12, 2026
Summary
Psilocybin-assisted psychotherapy (PAP) shows promise in reducing anhedonia, a challenging symptom of treatment-resistant depression (TRD). In a trial with 30 participants diagnosed with Major Depressive Disorder or Bipolar II Disorder, significant reductions in anhedonia were observed after a single 25 mg dose of psilocybin, as measured by the Snaith-Hamilton Pleasure Scale. Improvements were noted at both 3-month and 6-month follow-ups, suggesting that PAP could be a valuable intervention for enhancing quality of life in individuals suffering from TRD.
Abstract
Anhedonia, a core symptom of depression, is often resistant to conventional treatments and significantly impacts quality of life. This secondary an...
Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD
OpenAlex – February 11, 2026
Summary
Greater mystical experiences during psilocybin treatment significantly reduce obsessive-compulsive disorder (OCD) symptoms. In a clinical trial with 27 participants, those reporting stronger mystical experiences showed lower OCD severity at both one and twelve weeks post-treatment. Specifically, the Mystical subscale of the experience questionnaire correlated most consistently with symptom reduction. This suggests that the quality of subjective experiences during psilocybin therapy may enhance treatment effectiveness, highlighting the importance of optimizing therapeutic conditions for improved outcomes in OCD management.
Abstract
Background: Psilocybin treatment has shown promise across a range of psychiatric conditions. Mystical-type experiences during dosing sessions have ...
Activity-Dependent Neural Rewiring: Mechanisms of Psilocybin-Induced Cortical Network Reorganization
Zenodo (CERN European Organization for Nuclear Research) – February 06, 2026
Summary
Psilocybin has shown significant promise in treating mental health disorders by promoting structural neural plasticity. A review of recent findings highlights that psilocybin induces specific reorganization of cortical networks, enhancing sensory pathways while diminishing cortico-cortical connections. Using innovative techniques like monosynaptic rabies viral tracing, researchers mapped inputs to pyramidal neurons in the mouse brain, revealing that this rewiring is contingent on neural activity during treatment. These insights into psilocybin's mechanisms could pave the way for improved therapeutic strategies in psychology and pain management.
Abstract
Psychedelic compounds, particularly psilocybin, have demonstrated remarkable therapeutic potential for mental health disorders through mechanisms i...
Activity-Dependent Neural Rewiring by Psilocybin: A Monosynaptic Rabies Virus Tracing Study
Zenodo (CERN European Organization for Nuclear Research) – February 06, 2026
Summary
Psilocybin, the psychoactive compound in magic mushrooms, can induce significant neural rewiring, enhancing therapeutic potential for depression. A study involving 500 subjects revealed that psilocybin increases connectivity in sensory regions by up to 10% while reducing it in self-referential areas by 15%. Utilizing a genetically modified rabies virus for mapping, findings indicate that neural activity during psilocybin administration dictates which brain circuits are strengthened or weakened. This insight paves the way for precision psychedelic therapies tailored to individual sensory and cognitive experiences.
Abstract
Recent advances in neuroscience have revealed unprecedented insights into how psilocybin, the psychoactive compound in magic mushrooms, induces the...
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds.
Journal of psychopharmacology (Oxford, England) – February 05, 2026
Summary
Psilocybin and other psychedelics show significant promise for treating challenging mental health conditions like depression and mood disorders, offering hope for treatment resistance. However, advancing these therapies responsibly faces unique hurdles. Clinical trials must navigate issues like participants not responding to treatment, strong expectancy effects, and potential post-session psychological difficulties. Developing sophisticated strategies to manage these complexities is crucial to responsibly integrate psychedelics into psychiatric practice. Organizations are vital in guiding best practices for this emerging field.
Abstract
Classical psychedelics-a broad class of compounds that include psilocybin, lysergic acid diethylamide, dimethyltryptamine, and mescaline-have shown...
Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease.
Pharmacopsychiatry – February 05, 2026
Summary
Compelling evidence links chronic MDMA use to heart valve abnormalities in humans. A systematic review of 17 studies reveals that MDMA and LSD interact with a specific receptor pathway known to cause drug-induced heart valve damage. Lab and animal studies show both substances, with high and moderate affinity respectively, promote changes in heart valve cells. While no human cases of LSD-induced damage are reported, preclinical data supports its potential. This underscores the importance of cardiac safety monitoring in ongoing psychedelic research.
Abstract
Serotonergic psychedelics, such as lysergic acid diethylamide, and psilocybin, and the entactogen 3,4-methylenedioxymethamphetamine exhibit agonist...
MDMA and psilocybin regulate oligodendrocyte-lineage cell numbers and anxiety-like behaviors in a rat model of fear.
Biological psychiatry – February 03, 2026
Summary
Psilocybin and MDMA significantly reduce fear-related behaviors, acting through brain changes. In a study with 210 rats, these compounds promoted oligodendrocyte plasticity and myelination, crucial for brain function. Psilocybin specifically induced oligodendrogenesis, while MDMA enhanced mature myelin markers. Disrupting myelin abolished the anxiety reduction, highlighting how these psychedelics remodel brain circuitry. This suggests enhancing myelination could boost their therapeutic power for conditions like PTSD.
Abstract
Psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) produce rapid, enduring therapeutic effects in post-traumatic stress disorder (PTSD); howev...
Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia
Psychedelics. – February 03, 2026
Summary
Psilocybin, a hallucinogen, differentially affects social behavior and inflammation in female mice, crucial for Anorexia Nervosa. In an animal model, psilocybin didn't alter sociability in groups modeling anorexia or exercise, but increased social familiarity in controls. It elevated the proinflammatory cytokine IL-6, a marker of inflammation, in exercising mice, correlating with novelty-seeking. This psychology research illuminates biological mechanisms affecting social relations, emotional empathy, and anxiety, vital for understanding psychedelics' therapeutic potential, especially considering social isolation and prosocial behavior.
Abstract
Psychedelics, particularly psilocybin, have shown therapeutic potential across several psychiatric conditions, including depression, anxiety, obses...
Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin
Molecular Psychiatry – February 03, 2026
Summary
A compelling finding reveals the hallucinogen 2C-B causes less dysphoria than psilocybin, with distinct neural effects. Using functional magnetic resonance imaging in 22 healthy volunteers, brain mapping showed both compounds altered functional connectivity across key brain regions like the temporal lobe. 2C-B and psilocybin reduced intranetwork links while increasing between-network connections. 2C-B uniquely elevated transmodal functional connectivity. These serotonergic and monoaminergic effects, impacting brain activity, highlight 2C-B's potential in Neuroscience and Psychology for novel Mental Health and Psychiatry treatments and neuroplasticity studies.
Abstract
As psychedelic-assisted psychotherapy gains momentum, clinical investigation of next-generation psychedelics may lead to novel compounds tailored f...
Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot Study
Psychedelic Medicine – February 03, 2026
Summary
A compelling finding: Psilocybin, a serotonergic hallucinogen, initially hindered cognitive flexibility. In a touchscreen-based visual discrimination learning task, 16 rats were evaluated for cognition. Only 5 (31%) demonstrated associative learning. Psilocybin (1 mg/kg) impaired short-term learning/unlearning speed, a key aspect of cognitive psychology. Neuroscience indicates potential long-term enhancements, relevant for brain flexibility, impacting developmental psychology, audiology, drug studies, pain management, forensic toxicology, and psychedelics' complex effects.
Abstract
Introduction: Cognitive flexibility is essential for behavioral adaptation in response to environmental changes and is impaired in various neuropsy...
Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial
Mendeley Data – February 02, 2026
Summary
A compelling randomized controlled trial reveals a single psilocybin session dramatically boosts smoking cessation. Among 82 participants, 40.5% receiving this hallucinogen achieved prolonged abstinence at six months, versus just 10% using a nicotine patch. This medicine, administered without anesthesia, showed a 6.1 times higher likelihood of prolonged abstinence from nicotine. This novel approach in psychiatry offers robust promise for smoking cessation, with no serious adverse effects reported, presenting a powerful alternative to conventional treatments.
Abstract
BACKGROUND. Annual tobacco-related deaths are estimated at 480,000 in the US and 8 million worldwide, dwarfing mortality for all other drugs of abu...
Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.
Psychiatry research – February 02, 2026
Summary
Significant improvements in Anxiety and Depression were observed in 115 adults undergoing Psychedelic-assisted psychotherapy with LSD or Psilocybin. This real-world analysis, involving 56.5% women, showed substantial reductions in depressive symptoms (effect size η²=0.42) and anxiety (η²=0.17) 1-3 months post-treatment. Patients receiving either 100 µg LSD or 25 mg psilocybin reported similar positive outcomes, alongside improved emotional regulation. The experience, potentially including mystical elements, was well-tolerated with mild, transient adverse events, highlighting the effectiveness of this approach.
Abstract
Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from r...
Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance.
Neurologic clinics – February 01, 2026
Summary
Remarkably, patient expectation alone can profoundly impact depression treatment outcomes. This review explores how the powerful placebo effect shapes results in trials for new antidepressant therapies, especially with emerging psychedelic compounds like Psilocybin, Ketamine, and MDMA. It highlights how trial design, therapeutic setting, and expectancy interact. The challenge of 'unblinding' and the need for better 'masking' techniques are crucial to accurately assess these promising psychedelic treatments, ensuring we understand their true benefits beyond the placebo response.
Abstract
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has sti...
Psilocybin and Bipolar Depression: Promise and Prudence.
CNS drugs – February 01, 2026
Summary
Psilocybin, combined with psychotherapy, shows early promise for bipolar depression, a challenging condition affecting approximately 40 million people worldwide. Initial investigations involving 19 individuals with bipolar II disorder reveal encouraging results, suggesting a potential rapid-acting treatment where current options often fall short. However, careful investigation is crucial due to limited evidence and significant safety concerns, including potential mood switching and medication interactions. Rigorous research is essential to establish psilocybin's safety and effectiveness, particularly for bipolar I disorder and long-term outcomes, before broader application.
Abstract
Bipolar disorder affects approximately 40 million individuals worldwide, with depression being the most prominent phase of the illness. Owing to li...